MADISON, WI (April 5, 2021) – EyeKor, Inc., an innovative Contract Research Organization (CRO) specializing in medical imaging and data management for clinical studies, announced today the company will rebrand as MERIT CRO. The new brand identity follows the company’s recent acquisition of CompleWare Corporation, a CRO specializing in respiratory and cardiac safety solutions for the clinical trial industry.
“The MERIT rebrand provides a clear, united, progressive identity for our growing team,” said Yijun Huang, Co-founder and CEO of EyeKor. “It reflects the next stage of the company’s evolution as a clinical endpoint services provider. Our clients benefit from our complete package of clinical expertise, technology, and exceptional service with MERIT,” continued Huang.
MERIT is an innovative, global clinical trial endpoint services provider working in a variety of therapeutic areas, including ophthalmology, respiratory, oncology, cardiac safety, dermatology, and neurology. We partner with CROs as well as pharmaceutical and biotech companies to deliver reliable endpoint services in multi-regional clinical trials. Together our work advances and accelerates the improvement of therapeutic options for patients worldwide.
MERIT’s EXCELSIOR technology platform increases accuracy and efficiency by providing a suite of advanced endpoint analysis tools designed based on our extensive collaboration with biopharma companies. MERIT’s offices are located in Madison, WI, North Liberty, IA, and in Shanghai, China. We conduct studies across the globe with experience managing clinical sites in 58 countries.